Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

Medical education · Dr. Chloé Dubois

29 Aug 2026 · In person · Dr. Chloé Dubois, Vall d'Hebron · MSL Rachel Adeyemi · Vantrexa

ReviewedManualENG-0004—

Capture insight from this engagement

Location: Vall d'Hebron
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Chemotherapy-free first line

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

How should grade 2 infusion reactions be managed without steroids?

Notes

Medical education with oncology pharmacist at Vall d'Hebron. Discussed brain-metastasis subgroup data, chemotherapy-free first line.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 5
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0004

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
07 Sept 2026, 18:29 UTC	Update	GNGrace Nakamura	notes	Planned → Reviewed	—	UI